Clinical Trial

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2023 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
To explore the efficacy and safety of chidamide combined with endocrine in phosphoinositide-3-kinase,catalytic,alpha gene(PI3KCA) wild type hormone receptor positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients and to explore the efficacy and safety of Everolimus combined with endocrine therapy in patients with PI3KCA Mutant HR+/HER2- advanced breast cancer.
Trial Details
NCT Number NCT05983107
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions HR+/HER2- Advanced Breast Cancer, Targeted Therapy
Enrollment 102 participants
Start Date 2023-07-20
Primary Completion 2026-07-15 (estimated)
Study Completion 2027-07-15 (estimated)
Updated on ClinicalTrials.gov 2023-08-09